StreetInsider.com News Articles

USPTO allows Glucotrack patent for implantable glucose monitor

Wed, 08 Jul 2026 08:00:09 -0400

Glucotrack, Inc. (Nasdaq: GCTK) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application titled "Methods and Systems for Continuously Monitoring the Glucose Level of a Patient," covering its implantable continuous blood glucose monitoring platform.

The allowed claims cover implantable glucose monitoring systems that use an intravascular sensing lead coupled to an electronics assembly, including electrode configurations, lead-based sensing structures, and methods for continuous glucose measurement within the vasculature.

The new allowance adds to three CBGM patents the USPTO issued in late 2025 — US 12,453,494; US 12,458,257; and US 12,458,258 — further extending

Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform

Wed, 08 Jul 2026 08:00:00 -0400

RUTHERFORD, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application titled “Methods and Systems for Continuously Monitoring the Glucose Level of a Patient.” The allowed claims expand the intellectual property protecting the Company’s continuous blood glucose monitoring (CBGM) platform as it advances its multi-year, fully implantable CBGM system toward commercialization.

The

Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform

Wed, 08 Jul 2026 08:00:00 -0400

The

Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform

Wed, 08 Jul 2026 08:00:00 -0400

The

Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform

Wed, 08 Jul 2026 08:00:00 -0400

The

Form PRE 14A Glucotrack, Inc. For: Jun 17

Wed, 17 Jun 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260617/26660836.html

Form PRE 14A Glucotrack, Inc. For: Jun 17

Wed, 17 Jun 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260617/26660836.html

Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions

Tue, 26 May 2026 08:00:00 -0400

RUTHERFORD, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that company leadership will present on its fully implantable continuous blood glucose monitoring (CBGM) technology at the American Diabetes Association’s (ADA) 2026 Scientific Sessions, taking place in New Orleans, June 5 – 8, 2026.

As part of the ADA’s Innovation Hub, Mark Tapsak, PhD, Glucotrack’s Chief Scientific Officer, will present on the potential of next-generation CGM technology that addresses

Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions

Tue, 26 May 2026 08:00:00 -0400

As part of the ADA’s Innovation Hub, Mark Tapsak, PhD, Glucotrack’s Chief Scientific Officer, will present on the potential of next-generation CGM technology that addresses

Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions

Tue, 26 May 2026 08:00:00 -0400

As part of the ADA’s Innovation Hub, Mark Tapsak, PhD, Glucotrack’s Chief Scientific Officer, will present on the potential of next-generation CGM technology that addresses

Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions

Tue, 26 May 2026 08:00:00 -0400

As part of the ADA’s Innovation Hub, Mark Tapsak, PhD, Glucotrack’s Chief Scientific Officer, will present on the potential of next-generation CGM technology that addresses

Form 8-K Glucotrack, Inc. For: May 15

Fri, 15 May 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260515/26507114.html

Form 8-K Glucotrack, Inc. For: May 15

Fri, 15 May 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260515/26507114.html

Form SCHEDULE 13G/A Glucotrack, Inc. Filed by: ARMISTICE CAPITAL, LLC

Fri, 15 May 2026 11:18:00 -0400

si-local-file:///var/storage/secattach/20260515/26502073.html

Form SCHEDULE 13G/A Glucotrack, Inc. Filed by: ARMISTICE CAPITAL, LLC

Fri, 15 May 2026 11:18:00 -0400

si-local-file:///var/storage/secattach/20260515/26502073.html

Form 10-Q Glucotrack, Inc. For: Mar 31

Thu, 14 May 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260514/26496845.html

Form 10-Q Glucotrack, Inc. For: Mar 31

Thu, 14 May 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260514/26496845.html

Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights